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Background: This study examined potential predictors of remission among patients treated 
for major depressive disorder (MDD) in a naturalistic clinical setting, mostly in the Middle 
East, East Asia, and Mexico. 
Methods: Data for this post hoc analysis were taken from a 6-month prospective, 
noninterventional, observational study that involved 1,549 MDD patients without sexual dysfunc-
tion at baseline in 12 countries worldwide. Depression severity was measured using the Clinical 
Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology 
Self-Report (QIDS-SR
16
). Depression-related pain was measured using the pain-related items of 
the Somatic Symptom Inventory. Remission was defined as a QIDS-SR
16
 score 5. Generalized 
estimating equation regression models were used to examine baseline factors associated with 
remission during follow-up. 
Results: Being from East Asia (odds ratio [OR] 0.48 versus Mexico; P0.001), a higher 
level of depression severity at baseline (OR 0.77, P=0.003, for Clinical Global Impression 
of Severity; OR 0.92, P0.001, for QIDS-SR
16
), more previous MDD episodes (OR 0.92, 
P=0.007), previous treatments/therapies for depression (OR 0.78, P=0.030), and having any 
significant psychiatric and medical comorbidity at baseline (OR 0.60, P0.001) were negatively 
associated with remission, whereas being male (OR 1.29, P=0.026) and treatment with duloxetine 
(OR 2.38 versus selective serotonin reuptake inhibitors, P0.001) were positively associated 
with remission. However, the association between Somatic Symptom Inventory pain scores and 
remission no longer appeared to be significant in this multiple regression (P=0.580), (P=0.008 
in descriptive statistics), although it remained significant in a subgroup of patients treated 
with selective serotonin reuptake inhibitors (OR 0.97, P=0.023), but not in those treated with 
duloxetine (P=0.182). 
Conclusion: These findings are largely consistent with previous reports from the USA and 
Europe. They also highlight the potential mediating role of treatment with duloxetine on the 
negative relationship between depression-related pain and outcomes of depression. 
Keywords: antidepressant, duloxetine, selective serotonin reuptake inhibitors, Asia, Middle 
East, Mexico
Introduction
Major depressive disorder (MDD) is a highly prevalent condition that is associated 
with significant levels of disability, morbidity, and mortality. Most recently, the 
World Mental Health survey by the World Health Organization reported the lifetime 
prevalence of major depressive episode in 18 countries to range from 6.5% (People’s 
Republic of China) and 6.6% (Japan) to 21.0% (France) and 19.2% (the USA).1 While 
the prevalence estimates were found to be greater in Western countries, emerging 
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evidence suggests that the prevalence rates in other parts 
of the world may have been underestimated. According to 
statistics from the Organisation for Economic Co-operation 
and Development (OECD) for instance, the suicide rates in 
East Asian countries like South Korea or Japan have been 
far above the OECD average.2 In addition, the 2010 Global 
Burden of Disease study revealed that the relative size of 
MDD burden, measured in disability-adjusted life years, was 
greater in the Middle East and North Africa than anywhere 
else, particularly for women in these regions.3,4 These find-
ings reinforce the importance of treating MDD and related 
health problems as a public health priority, not only in the 
Western world, but in non-Western countries as well.
While treatment objectives have traditionally been cen-
tered around a reduction of symptoms, emerging evidence 
has shown that patients who experience clinically meaningful 
improvement but still have residual symptoms frequently 
experience significant levels of psychosocial impairment, and 
are also more vulnerable to relapse and recurrences of the 
disorder than patients who achieve full remission.5–7 Thus, 
there has been a growing emphasis on the importance of 
achieving remission in the treatment of MDD. This requires 
the development and implementation of treatment strategies 
that can increase the chances of achieving remission. Identi-
fying predictors of remission in MDD is likely the first step, 
and can help guide clinical decision-making in heterogeneous 
patient populations. 
Numerous studies have identified predictors of poor treat-
ment outcomes of depression. However, most of these studies 
have employed “response” or “symptom improvement/wors-
ening” rather than “remission” as an outcome, and have also 
been conducted in experimental settings with highly selected 
patient populations, possibly limiting generalizability to actual 
clinical practice. Two notable exceptions are the US Sequence 
Treatment Alternative to Relieve Depression (STAR*D) 
study8 and the South Korean Clinical Research Centre for 
Depression study,9 both of which were carried out in “real 
world” settings. The former found that being Caucasian, being 
female, and having higher levels of education or income were 
positively associated with remission, whereas longer index 
episodes, more concurrent psychiatric and medical disorders, 
and lower functioning and quality of life at baseline were 
negatively associated with remission. This study also revealed 
the negative impact of painful physical symptoms,10 somatic 
symptomatology,11 concurrent alcohol and drug use,12 anxiety 
disorder13 and atypical features14 on remission. Similarly, 
the Clinical Research Centre for Depression study found the 
following potential predictors of remission: being female, no 
history of suicide attempt, and lower baseline severity of anxi-
ety. A recent systematic review, which included a wide array 
of published studies on predictors of poor treatment outcomes 
of depression,15 reported similar findings, although it pointed 
out that the relationship between some of the factors (sex and 
severity of depression in particular) and treatment outcome 
could vary by class of antidepressant, treatment modality, 
and study outcomes. Nevertheless, given that most of the 
evidence comes from the USA and Europe, further research 
should examine whether these findings are also valid in other 
ethnic groups and cultures. 
This study examined the baseline features associated with 
remission in the treatment of MDD for up to 6 months in a 
naturalistic clinical setting, mostly in the Middle East, East 
Asia, and Mexico, using data from a 6-month prospective 
observational study.
Materials and methods
study design
Data for this post hoc analysis were taken from a 6-month, 
international, prospective, noninterventional, observational 
study, primarily designed to examine treatment-emergent 
sexual dysfunction and other treatment outcomes among 
patients with MDD who were treated with either a selective sero-
tonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine 
reuptake inhibitor (SNRI) in actual clinical practice. A total 
of 1,647 patients were enrolled at 88 sites between November 
15, 2007 and  November 28, 2008. Of these, the 1,549 
patients were classified as “sexually active patients without 
sexual dysfunction at study entry”, and included in the study. 
The patients were drawn from the following countries and 
regions across the globe: East Asia (People’s Republic of 
China [n=205; 13.2%], Hong Kong [n=18; 1.2%], Malaysia 
[n=33; 2.1%], the Philippines [n=113; 7.3%], Taiwan [n=199; 
12.8%], Thailand [n=17; 1.1%], and Singapore [n=2; 0.1%]), 
the Middle East (Saudi Arabia [n=179; 11.6%] and the United 
Arab Emirates [n=135; 8.7%]), Mexico (n=591; 38.2%), and 
other regions (Israel [n=9; 0.6%] and Austria [n=48; 3.1%]). 
This study followed the ethical standards of responsible local 
committees and the regulations of the participating countries, 
and was conducted in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki and are 
consistent with Good Clinical Practice where applicable to 
a study of this nature. Ethical review board approval was 
obtained as necessary for observational studies wherever 
required by local law. All patients provided informed consent 
for the provision and collection of the data. Further details of 
the study design have been published elsewhere.16,17
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study population
Patients (on an outpatient basis) were eligible to participate in 
the study if they met the following inclusion criteria: present-
ing with an episode of MDD within the normal course of care, 
with MDD diagnosed according to the International Statisti-
cal Classification of Diseases Tenth Revision18 or Diagnostic 
and Statistical Manual of Mental Disorders Fourth Edition 
Text Revision (DSM-IV-TR)19 criteria; at least moderately 
depressed, defined by the Clinical Global Impression of 
Severity (CGI-S, with a score of 4);20 initiating or switch-
ing to any available SSRI or SNRI antidepressant in any of 
the participating countries, in accordance with a treating 
psychiatrist’s discretion; at least 18 years of age; sexually 
active (with partner or autoerotic activity, including during 
the 2 weeks prior to study entry) without sexual dysfunction, 
as defined by the Arizona Sexual Experience Scale (ASEX,21 
ie, the criteria for sexual dysfunction: ASEX total score 19, 
ASEX score 5 on any item, or ASEX score 4 on any three 
items); and not participating in another currently ongoing 
study. The study excluded patients who had: a history of 
treatment-resistant depression (defined as failure to respond 
to treatment with two antidepressants from different classes 
at therapeutic doses for 4 weeks); a past or current diag-
nosis of schizophrenia, schizophreniform or schizoaffective 
disorder, bipolar disorder, dysthymia, mental retardation or 
dementia; or received any antidepressant within one week 
(one month for fluoxetine) prior to study entry, with the 
exception of patients receiving an ineffective treatment for 
whom immediate switch to an SSRI or SNRI antidepressant 
was considered to be the best treatment option. 
Treatment decisions were made solely at the discretion 
of the treating psychiatrist, and were independent of study 
participation. Patients were not required to continue taking 
the medication initiated at baseline. Changes in medication 
and dosing, as well as use of concomitant medications and 
nonpharmacological therapies for the treatment of depres-
sion, were possible at any time as determined by the treating 
psychiatrist. 
Data collection and outcome assessment
Data collection for the study occurred during visits within 
the normal course of care. The routine outpatient visit at 
which patients were enrolled served as the time for baseline 
data collection. Subsequent data collection was targeted at 
weeks 8, 16, and 24 following the baseline visit. Patient 
demographics and clinical history were recorded at the base-
line assessment. Clinical severity of depression was assessed 
by treating psychiatrists at each visit using the CGI-S and 
16-item Quick Inventory of Depressive Symptomatology 
Self-Report (QIDS-SR
16
).22 Remission was defined as a 
QIDS-SR
16
 score 5 at any time during the study period. This 
is more or less equivalent to a score of 7 on the 17-item 
Hamilton Depression Rating Scale.23,24 Depression-related 
pain severity was also measured using the pain-related items 
of the Somatic Symptom Inventory (SSI).25
statistical analysis
This post hoc study examined baseline predictors of (time-
varying) remission (ie, measured at each post-baseline visit) 
in the treatment of MDD. In order to minimize the confound-
ing effect of medication over the course of treatment, we 
included only those patients who started with duloxetine or 
an SSRI as “monotherapy” (n=1,480), and analyzed patient 
observations up to the point where their initial medications 
were maintained (n=1,062 [71.8%] evaluable observations 
available at 24 weeks). Of the 1,480 patients, 1,194 were 
included in the final analysis because they were not in remis-
sion at baseline (ie, a QIDS-SR
16
 score 5) and also provided 
at least one post-baseline QIDS-SR
16
 assessment (n=1,018 
[85.3%] evaluable observations available at 24 weeks). 
Baseline characteristics of patients who did (n=939) or 
did not (n=255) achieve remission during follow-up were 
first described and compared using the t-test (for continuous 
variables) and chi-squared test (for categorical variables). 
Generalized estimating equation regression models with 
an exchangeable correlation structure were used to examine 
baseline factors associated with remission during follow-up, 
adjusting for visit numbers. The models included remission 
as a time-varying dependent variable, and also the following 
explanatory variables measured at baseline: age (years), sex 
(male/female), region (East Asia/the Middle East/Mexico/
other region), CGI-S score, QIDS-SR
16
 total score, SSI pain 
total score, and treatment (duloxetine/SSRI) at baseline. In 
addition, the following baseline variables were included if 
they appeared to be significant at P0.1 in simple generalized 
estimating equation analyses (ie, one explanatory variable at 
once): age at first episode of MDD (years), body mass index 
(kg/m2), independent living (yes/no), living with a spouse/
partner (yes/no), educational attainment (up to primary 
school/secondary school or occupational program/up to uni-
versity), employment status (full-time/economically inactive/
unemployed or part-time), number of MDD episodes in the 
24 months prior to baseline, the receipt of any treatments/
therapies for depression in the 24 months prior to baseline 
(yes/no), and having any significant psychiatric and medical 
comorbidities (yes/no). 
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These analyses were repeated for each treatment cohort 
(duloxetine and SSRIs) as well as for each region (Middle 
East, East Asia, and Mexico), except for “other region” due 
to a small sample size. All statistical analyses were carried 
out in SAS version 9.3 (SAS Institute, Cary, NC, USA). 
Results
Of the 1,194 patients included in the final analysis, 42.4% 
(n=506) initiated duloxetine and the rest initiated an SSRI 
antidepressant (57.6%; n=688) at baseline. The most com-
mon SSRIs prescribed at baseline were paroxetine (25.3%), 
escitalopram (24.1%), sertraline (20.5%), and fluoxetine 
(19.3%). The median daily doses of these medications at 
baseline were 60 mg/day for duloxetine, 20.0 mg/day for 
paroxetine, 10.0 mg/day for escitalopram, 50.0 mg/day for 
sertraline, and 20.0 mg/day for fluoxetine.
A total of 939 patients (78.6%) achieved remission during 
the 6-month follow-up period. Remission rates were higher 
in the Middle East (82.9%) and Mexico (85.1%) than in 
East Asia (69.7%) and other regions, ie, Israel and Austria 
(58.1%, P0.001). It was also higher in patients who initi-
ated duloxetine when compared with patients who initiated 
SSRIs (84.0% versus 74.7%, P0.001); a similar pattern 
was observed in each region (76.2% versus 63.1% for East 
Asia, 91.0% versus 72.9% for the Middle East, and 90.8% 
versus 82.7% for Mexico, P0.05 for all). 
Table 1 describes the baseline demographics and clini-
cal characteristics of patients by remission status during 
follow-up. Compared with those patients who did not achieve 
remission during follow-up, patients who achieved remis-
sion were more likely to be male, living in the Middle East 
or Mexico, living with a spouse/partner, have a higher level 
of education, and have initiated duloxetine (versus SSRI), 
but were less likely to have received treatments/therapies 
for depression in the past 24 months or to have significant 
concurrent psychiatric and medical conditions at baseline. 
In addition, these patients, on average, had slightly lower 
levels of clinical severity (measured by QIDS-SR
16
) and 
depression-related pain (measured by SSI pain) as well as a 
lower number of MDD episodes at baseline. 
The results of multiple (generalized estimating equation) 
regression, which examined baseline patient characteristics 
associated with a time-varying remission over a 6-month 
period, are shown in Table 2. The associations listed above 
were largely maintained in this multiple regression analysis, 
except for SSI pain score. Patients who were male (odds ratio 
[OR] 1.29; P=0.026) and initiated duloxetine at baseline (OR 
2.38; P0.001) were more likely to achieve remission during 
follow-up. Meanwhile, those patients who were living in East 
Asia (OR 0.48 versus Mexico; P0.001) or other regions 
(OR 0.38 versus Mexico; P=0.004), had higher CGI-S (OR 
0.77; P=0.003) and QIDS-SR
16 
(OR 0.92; P0.001) scores, 
had more MDD episodes during the past 24 months (OR 
0.92; P=0.007), had received treatments/therapies for MDD 
in the past 24 months (OR 0.78; P=0.030), and had significant 
psychiatric and medical comorbidities (OR 0.60; P0.001) 
at baseline were less likely to achieve remission during 
follow-up. However, as already mentioned, the association 
between SSI pain scores and remission no longer appeared 
to be significant (OR 0.99; P=0.580), although it remained 
significant in a subgroup of patients who initiated on SSRIs 
(OR 0.97; P=0.023), but not in those initiated on duloxetine 
(OR 1.03; P=0.182; data not shown). 
These analyses were repeated for each region (East Asia, 
the Middle East, and Mexico) as shown in Table 3. The results 
remained largely consistent in each of the subgroup analyses, 
but with fewer significant factors. As in the main analysis, the 
level of clinical severity (measured by CGI-S or QIDS-SR
16
) 
and type of medication initiated were consistently associated 
with remission during follow-up. Patients who were more 
severely ill were less likely to achieve remission (OR 0.68, 
P=0.021 [CGI-S] in East Asia; OR 0.88, P=0.002 [QIDS-
SR
16
] in the Middle East; OR 0.90, P0.001 [QIDS-SR
16
] 
in Mexico), whereas those who initiated duloxetine (versus 
SSRIs) were more likely to achieve remission across the 
regions (OR 2.58, P0.001 in East Asia; OR 2.78, P0.001 
in the Middle East; OR 1.95, P0.001 in Mexico). Other fac-
tors significantly associated with (lower odds of) remission 
were the receipt of previous treatments/therapies for MDD 
(OR 0.69; P=0.049) in East Asia, more MDD episodes (OR 
0.77; P0.001) in the Middle East, and having significant 
psychiatric and medical comorbidities (OR 0.63; P=0.004) 
in Mexico. With regard to the association between SSI pain 
scores and remission, a pattern similar to that in the main 
analysis was observed in each of these subgroup analyses. 
However, unlike in the main analysis, the odds of achieving 
remission in patients with higher SSI pain scores were only 
numerically (ie, not significantly) lower than those with lower 
pain scores in SSRI-initiated patients. 
Discussion
The present analysis, using data from a prospective obser-
vational study, identified baseline features associated with 
remission in MDD patients treated with duloxetine or an 
SSRI for up to 6 months in actual clinical practice settings, 
mostly in the Middle East, East Asia, and Mexico. Our 
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Table 1 Patient characteristics by remission status during follow-up
Baseline characteristic No remission (n=255) Remission (n=939) P-value
age (years), mean (sD) 38.6 (10.9) 37.6 (10.2) 0.162
sex 0.029
Male, % 36.5 44.1
Female, % 63.5 55.9
region, % 0.001
east asia 49.0 30.7
Mexico 29.8 46.2
The Middle east 16.1 21.2  
Other region 5.1 1.9
ethnicity, % 0.001
east asian 49.4 30.8
hispanic 29.8 45.8
Mediterranean/Middle eastern/North africa descent caucasian 14.1 17.6
european caucasian 4.3 2.7
West asian (indian subcontinent) 2.0 3.0
african 0.4 0.2
Age at first symptoms of MDD (years), mean (SD) 33.6 (11.8) 33.8 (10.9) 0.800
BMi (kg/m2), mean (sD) 24.4 (4.7) 24.8 (4.3) 0.302
independent living, % 19.2 15.4 0.147
living with a spouse/partner, % 62.8 74.5 0.001
educational attainment, % 0.009
Primary school or lower 11.4 6.8
secondary school/occupational program 47.1 42.7
University or higher 41.6 50.5
employment status, % 0.129
Full-time 51.0 57.6
economically inactive 28.2 25.9
Unemployed/part-time 20.8 16.5
cgi-s, mean (sD) 4.6 (0.7) 4.5 (0.7) 0.646
QiDs-sr16, mean (sD) 15.8 (4.6) 14.2 (4.3) 0.001
ssi pain, mean (sD) 15.4 (5.5) 14.4 (4.8) 0.008
Number of MDD in the past 24 months, mean (sD) 1.7 (2.6) 1.2 (1.7) 0.005
any treatments/therapies for depression in the past 24 months, % 52.6 39.1 0.001
Having significant comorbidities, % 28.9 22.4 0.031
Treatment with duloxetine (versus ssri), % 31.8 45.3 0.001
Notes: Data are presented as the percentage or the mean (standard deviation) as appropriate. Further details of the baseline characteristics of the study sample have been 
published elsewhere.16,17
Abbreviations: sD, standard deviation; BMi, body mass index; MDD, major depressive disorder; cgi-s, global impressions of severity; QiDs-sr16, 16-item Quick inventory 
of Depressive symptomatology self-report; ssi pain, somatic symptom inventory; ssri, selective serotonin reuptake inhibitor.
results revealed relatively high rates of remission, ie, about 
79% of patients achieved remission during follow-up, with 
the rate being higher in the Middle East (83%) and Mexico 
(85%) than in East Asia (70%) and other regions (58%). 
Several baseline features were found to be associated with 
higher remission rates, including being from the Middle 
East or Mexico, being male, having lower baseline severity 
of depression, fewer previous MDD episodes, no significant 
psychiatric and medical comorbidities, and being treated with 
duloxetine. Similar baseline features were identified as poten-
tial predictors of remission in subgroup analyses by region. 
These findings were generally consistent with those reported 
by the US STAR*D study,8 a large-scale prospective clinical 
trial carried out in a naturalistic clinical setting, confirming 
that this set of predictors of remission in MDD are mostly 
valid across different ethnic groups and cultures. 
However, it should be noted that our remission rates, 
particularly in the Middle East and Mexico, were somewhat 
higher than those found in other studies. For instance, the 
STAR*D study reported a remission rate of 33% (defined as 
an exit score of 5 on QIDS-SR
16
) among patients treated 
with citalopram (an SSRI) for up to 14 weeks,8 although it 
also noted a theoretical cumulative remission rate of 67% 
after four acute treatment steps (up to 14 weeks for each step). 
In addition, recent meta-analyses reported remission rates of 
40% for duloxetine and 38% for SSRIs with pooled data from 
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Table 2 Baseline factors associated with remission during follow-up (whole sample)
Variables Adjusted OR* OR 95% CI P-value
Being older 0.99 0.98–1.00 0.184
Being male (versus female) 1.29 1.03–1.62 0.026
region (versus Mexico)
east asia 0.48 0.37–0.63 0.001
Middle east 0.82 0.60–1.12 0.216
Other region 0.38 0.20–0.73 0.004
living with spouse/partner 1.23 0.96–1.58 0.103
educational attainment (versus primary school or lower)
secondary school/occupational program 1.03 0.70–1.51 0.885
University or higher 1.28 0.86–1.90 0.223
employment status (versus full-time employment)
economically inactive 1.03 0.79–1.34 0.823
Unemployed/part-time 0.86 0.65–1.13 0.278
higher cgi-s score 0.77 0.65–0.91 0.003
higher QiDs-sr16 score 0.92 0.90–0.95 0.001
higher ssi pain score 0.99 0.97–1.02 0.580
More MDD episodes in the past 24 months 0.92 0.86–0.98 0.007
any treatment/therapies for MDD in the past 24 months 0.78 0.63–0.98 0.030
Having significant comorbidities 0.60 0.47–0.76 0.001
Treatment with duloxetine (versus ssri) 2.38 1.90–2.98 0.001
Notes: *This multiple regression included remission as a time-varying variable during follow-up, and was also adjusted for visit numbers.
Abbreviations: CI, confidence interval; OR, odds ratio; MDD, major depressive disorder; CGI-S, Global Impressions of Severity; QIDS-SR16, 16-item Quick inventory of 
Depressive symptomatology self-report; ssi pain, somatic symptom inventory; ssri, selective serotonin reuptake inhibitor.
Table 3 Baseline factors significantly associated with remission in each region*
Variables Adjusted OR OR 95% CI P-value
East Asia
Being older 1.00 0.98–1.02 0.888
Being male (versus female) 1.00 0.70–1.42 0.983
higher cgi-s score 0.68 0.50–0.94 0.021
any treatment/therapies for MDD in the past 24 months 0.69 0.47–0.998 0.049
Treatment with duloxetine (versus ssri) 2.58 1.77–3.76 0.001
Middle East
Being older 1.00 0.97–1.03 0.892
Being male (versus female) 1.83 0.98–3.40 0.058
higher QiDs-sr16 score 0.88 0.81–0.95 0.002
More MDD episodes in the past 24 months 0.77 0.66–0.90 0.001
Treatment with duloxetine (versus ssri) 2.78 1.66–4.66 0.001
Mexico
Being older 1.00 0.98–1.01 0.491
Being male (versus female) 1.29 0.91–1.84 0.157
higher QiDs-sr16 score 0.90 0.86–0.93 0.001
Having significant comorbidities 0.63 0.46–0.87 0.004
Treatment with duloxetine (versus ssri) 1.95 1.37–2.78 0.001
Notes: *Only significant factors are presented in this table, except for age and sex. This multiple regression included remission as a time-varying variable during follow-up, 
and was also adjusted for visit numbers.
Abbreviations: CI, confidence interval; OR, odds ratio; MDD, major depressive disorder; CGI-S, Global Impressions of Severity; QIDS-SR16, 16-item Quick inventory of 
Depressive symptomatology self-report; ssri, selective serotonin reuptake inhibitor.
six 8-week clinical trials (defined as an exit score of 5 on 
the 17-item Hamilton Depression Rating Scale),26 52% for 
mirtazapine (a newer antidepressant with noradrenergic and 
specific serotonergic effects) and 47% for SSRIs with clinical 
trials lasting at least 8 weeks.27 Although it is not clear why 
our remission rates were higher than those rates published, 
one possible reason can be found in the characteristics 
of our patient sample, ie, this was an observational study 
designed primarily to assess the frequency of treatment-
emergent sexual dysfunction in the treatment of MDD and 
thus included only those patients who were sexually active 
without sexual dysfunction at baseline. It is possible that such 
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patients could have a better MDD prognosis than those with 
sexual dysfunction. Notably, rates of antidepressant switch 
or augmentation in this observational study were also found 
to be very low (0.6%–2%).16 However, this still does not 
explain why patients in the Middle East and those in Mexico 
had higher remission rates. We may first need to understand 
whether patients who sought help and were treated for psy-
chiatric illness could represent the general MDD populations 
in the regions, particularly in the Middle East, where mental 
illness and the use of mental health services carry an intense 
and enduring stigma.28,29
Nevertheless, our findings regarding factors associated 
with remission were generally consistent with those of the 
STAR*D study.8 The exceptions were the impacts of sex 
and depression-related pain, as well as the superiority of 
duloxetine over SSRIs (not examined in the STAR*D) in 
achieving remission. First of all, our study found a positive 
association between being male and remission, probably 
mainly influenced by the Middle East, which was in fact the 
only region showing a significant association between these 
two factors at the regional level, albeit marginal at the 10% 
significance level (P=0.058). This observation contrasts with 
the findings of the STAR*D, which reported higher remission 
rates among females. The impact of sex on remission is not 
conclusive in the literature either. A recent systematic review 
on predictors of treatment outcomes in patients with depres-
sion reported mixed findings for the association between sex 
and treatment outcome.15 The review identified only one 
study showing a modest sex effect out of the seven studies 
involving tricyclic antidepressants. As in our study, a higher 
proportion of males were found to respond to imipramine,30 
whereas females were found to be more likely than males 
to respond to SSRIs.15 Although the association between 
sex and remission has not been well established as yet, our 
findings are consistent with the recent report from the Global 
Burden of Disease 2010 study, which identified the highest 
burden of MDD to be in the Middle East and North African 
regions, particularly among females. Taken together, these 
findings imply that the stigma attached to mental illness 
as well as psychological distress is more severe in Arabic 
women, potentially resulting in poorer outcomes. More effort 
should be made to better understand the mental health needs 
of Arabic women as well as cultural and contextual factors 
associated with their mental health.
Although depression-related pain initially did not appear 
to be a potential predictor of remission in the whole sample, 
the findings of our subgroup analyses by treatment cohort are 
in line with those of previous studies. Clinical trials and case 
reports have shown that treatment with antidepressants may 
help decrease pain in patients with depression and in those 
with pain alone, and that the existing evidence suggests that 
SNRIs, including duloxetine, may be more effective than 
SSRIs for the relief of painful physical symptoms.10,31–37 
Consistent with these results, patients taking duloxetine 
achieved the same level of remission independent of pain 
severity at baseline in our subgroup analyses, whereas this was 
not found for the subgroup of patients taking SSRIs. That is, 
patients taking SSRIs who had a higher level of pain sever-
ity at baseline did not achieve the same level of remission as 
those taking SSRIs who had a lower level of pain severity at 
baseline, confirming the negative impact of pain on achieving 
remission in this cohort (but not in the duloxetine cohort nor 
in the whole sample). 
This may in part explain our finding that duloxetine-
treated patients were more likely than SSRI-treated patients 
to achieve remission, especially given that 53% of our 
patients had painful physical symptoms at baseline (defined 
as an average score 2 for pain-related items on the SSI). 
In addition, there is limited evidence that SNRIs might be 
more efficacious than SSRIs in those patients with more 
severe MDD,26 and our study included at least moderately 
ill patients (defined as a CGI-S score 4). Nevertheless, “no 
sexual dysfunction”, another inclusion criterion, makes it 
hard to understand the impact of clinical severity on differ-
ent treatment outcomes. Further research is clearly required 
to investigate the relationships and interactions between 
depression-related pain, type of treatment, severity of illness, 
presence/absence of sexual dysfunction, and outcomes of 
treatment for depression. 
Our study has several limitations that should be taken into 
account when interpreting these results. First, as mentioned 
earlier, this study included only patients who were sexually 
active without sexual dysfunction at baseline because its 
primary objective was to assess the frequency of treatment-
emergent sexual dysfunction in the treatment of MDD. Sexual 
dysfunction has been reported to be two to three times more 
prevalent in patients with depression compared with the gen-
eral population,38,39 and thus our findings may not be imme-
diately generalizable to MDD patients as a whole. Further 
research is warranted to examine whether these findings can 
be replicated in MDD patients without such inclusion criteria. 
Nevertheless, our findings are generally in line with those 
of the STAR*D study. Second, although our study prospec-
tively assessed the level of depression severity (and thereby 
remission as well) in a “real-world” setting, the associations 
found in our study may not imply causal relationships given 
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its observational design. Third, although this observational 
study included more than 1,000 patients, these patients may 
not be representative of those with MDD in each region. 
Finally, a multiplicity of analyses was not adjusted for in 
these exploratory analyses, given that this study was designed 
to be hypothesis-generating, not hypothesis-testing.
Conclusion
The results of this 6-month prospective observational study 
identify a number of potential predictors of remission in the 
treatment of MDD in the Middle East, East Asia, and Mexico, 
where such information is very limited. Similar to several 
previous studies in the USA and Europe, a higher level of 
depression severity, more previous MDD episodes, previous 
treatments/therapies for depression, and having significant 
psychiatric or medical comorbidity were negatively associated 
with remission, whereas being male and treatment with dulox-
etine (versus SSRIs) were positively associated with remission. 
We also found that patients taking duloxetine, unlike those tak-
ing SSRIs, achieved the same level of remission independently 
of their pain severity at baseline. This suggests that the negative 
impact of pain on remission may be mitigated somewhat by 
treatment with duloxetine, which may in turn help to explain 
the higher remission rates found for duloxetine-treated patients. 
Further research is needed to improve our understanding of 
the complex relationships between depression-related pain, 
treatment with antidepressants, and outcomes of depression. 
Overall, these findings may help to guide clinical decision-
making in MDD for heterogeneous patient populations, 
particularly in non-Western countries. 
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